Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience

Garcı́a-Gallo, C. López; Fadul, Christian García; Laporta, Rosalía; Portero, Francisca; Millán, Isabel; Ussetti, Piedad

doi:10.12659/aot.894694

Cited by 11 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…178 There are several published reports of potential benefit to the addition or sole use of CMVIg for prophylaxis, but, because of the limited data to support routine use, the addition of CMVIg is not routinely recommended. 178,191 The most recent consensus guidelines note that some experts add CMVIg for intermediate and higher-risk recipients, but there are no randomized studies indicating that CMVIg is any better than GCV or valganciclovir alone.…”

Section: Cytomegalovirusmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Respiratory viruses are common in solid organ and hematopoietic stem cell transplant recipients and a recognized cause of significant morbidity and mortality. Epidemiology, risk factors, and attributable mortality in both populations are reviewed. In addition, virus-specific prevention and treatment options, including emerging investigational therapies, are discussed for respiratory syncytial virus, influenza, adenovirus, parainfluenza, and other respiratory viruses.

show abstract

Section: Cytomegalovirusmentioning

confidence: 99%

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Paulsen

Danziger‐Isakov

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

show abstract

“…Although treatment with hyperimmune globulin did not significantly modify the course of primary CMV infection during pregnancy (19), CMV-specific hyperimmune globulin lowered the risk of maternal-fetal transmission and ameliorated the disease sequelae (31). Prophylactic administration of IVIG or valaganciclovir and IVIG benefits transplant recipients (6,12,23,30,32,48).…”

Section: Introductionmentioning

confidence: 99%

Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells

et al. 2017

View full text Add to dashboard Cite

Intravenous immunoglobulin (IVIG) is used to treat or prevent severe viral infection, especially cytomegalovirus (CMV) infections. IVIG was characterized to understand its interaction with CMV-infected cells. IVIG retarded CMV spread and reduced virus yields depending on the neutralizing (NT) antibody titer. Immediate early protein synthesis was reduced by IVIG in 3 to 15 h, and IVIG specifically reduced the ratio of 66/68k protein synthesis among immediate early proteins in an NT antibody-dependent manner between 4 and 8 h after infection, indicating that antigenic modulation of CMV-infected cells by IVIG reduced viral protein synthesis and virus production. The half-life of antibody bound to CMV-infected cells was 3.8 h. NT antibody titers to varicella-zoster virus (VZV) and CMV in IVIG were dose dependently absorbed by cells infected with VZV and CMV, respectively, but the antibody titers to CMV and VZV, respectively, were not affected. NT antibody in 0.3 mL of IVIG (15 mg) was specifically absorbed by 10 CMV-infected cells and 10 VZV-infected cells, suggesting that the NT antibody in IVIG might be inactivated by one-tenth of a similar volume of CMV-infected or VZV-infected cells. Various antiviral activities of IVIG may contribute to control and alleviation of CMV infection.

show abstract

“…Due to major differences in clinical settings and in patient management between SOT and HSCT, and to avoid introducing heterogeneity bias into the analysis, the four HSCT studies were excluded from the meta-analysis (Figure 1). Thus, a total of 32 SOT studies were included in this meta-analysis (Figure 1) [24][25][26][28][29][30][31][32][33][34][35][36][37][38][40][41][42][43][44][46][47][48][49][50][51][52][53][54][55][56][57][58]. The most frequently used prophylactic CMVIG regimen involved the administration of 150 mg/kg within 72 h of transplantation and every 2 weeks thereafter.…”

Section: Search Resultsmentioning

confidence: 99%

Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

Barten¹,

Baldanti

Staus

et al. 2022

Life

View full text Add to dashboard Cite

Cytomegalovirus (CMV) is a common infection occurring in patients undergoing solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). CMV-specific hyperimmunoglobulin (CMVIG) has been used for the past four decades and is typically administered either prophylactically or pre-emptively. The present meta-analysis evaluated CMV infection rates in SOT patients who received prophylactic CMVIG. PubMed and the Cochrane Library were searched for studies published up to October 2021. The primary endpoint was CMV infection rate. Thirty-two SOT studies were identified (n = 1521 CMVIG-treated and n = 1196 controls). Prophylactic CMVIG treatment was often associated with a lower risk of CMV infection in transplant recipients. The average CMV infection rate was 35.8% (95% confidence interval [CI]: 33.4–38.2%) in patients treated prophylactically with CMVIG and 41.4% (95% CI: 38.6–44.2%) in the control group not receiving CMVIG (p = 0.003). Similar results were observed in analyses limited to publications evaluating currently available CMVIG products (Cytotect CP and Cytogam; p < 0.001). In combination with the established safety profile for CMVIG, these results suggest that prophylactic CMVIG treatment in patients undergoing solid organ transplantation may be beneficial, particularly in those at high risk of CMV infection or disease.

show abstract

Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience

Cited by 11 publications

References 0 publications

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation

Interaction of Immunoglobulin with Cytomegalovirus-Infected Cells

Effectiveness of Prophylactic Human Cytomegalovirus Hyperimmunoglobulin in Preventing Cytomegalovirus Infection following Transplantation: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About